FLSC

10.0800.10%
WC

William Carl Fairey

Independent Director

Mr. William Carl Fairey, Jr., also known as Bill, is Independent Director of KalVista Pharmaceuticals, Inc. since April 22, 2024. He serves as an Independent Director at Rein Therapeutics Inc. (formerly known as Aileron Therapeutics, Inc.) since October 31, 2023. He serves as an Independent Director at Mirum Pharmaceuticals, Inc. and Lung Therapeutics, Inc. since August 2021. He serves as an Independent Director at Ascendis Pharma A/S since 2022 as well as Respira Therapeutics, Inc. He served as Chief Commercial Officer and Executive Vice President of MyoKardia, Inc. since January 23, 2019 to November 2020. Mr. Fairey served as the Chief Operating Officer and Executive Vice President of ChemoCentryx, Inc. since January 8, 2018 until January 18, 2019. Mr. Fairey served as President at Actelion Pharmaceuticals US, Inc. from 2013 to 2017. Prior to that, he served in numerous positions with Actelion Pharmaceuticals Ltd since 2001, including Head of Actelion's Asia Pacific Region (2008 2012) and President of Actelion Pharmaceuticals Canada Inc. from 2003 to 2008. Prior to ChemoCentryx, he served in several roles at Actelion Pharmaceuticals, including chairing the Actelion China Board of Directors and becoming President of the U.S. division. Mr. Fairey has gained FDA approval and launched three significant products: OPSUMIT and UPTRAVI for PAH and VALCHLOR for MF CTCL. He has served as Director of California Life Sciences Association since October 31, 2016. He has also held several senior business, sales and market access roles at the Parke-Davis division of Warner-Lambert and has previously served on several life science company boards. He holds an MBA degree from Saint Mary's College of California and a Bachelor of Science degree in Biology from the University of Oregon. He is Independent Director of Frazier Life Sciences Acquisition Corp II from September 2026.

Positions